An Open-Label, Multicenter, Adaptive, Phase Ib/II Study of QL1706 or QL1604 Plus Bevacizumab As First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Bevacizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined